Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2287)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 10.06.24 17:53:37 von
neuester Beitrag 10.06.24 17:53:37 von
Beiträge: 23.628
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 861
Gesamt: 1.276.377
Gesamt: 1.276.377
Aktive User: 11
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVV1
14,700
EUR
-12,57 %
-2,114 EUR
Letzter Kurs 17:59:30 Tradegate
Neuigkeiten
TitelBeiträge |
---|
13:03 Uhr · Felix Haupt Anzeige |
07.06.24 · LYNX Analysen Anzeige |
23.05.24 · wallstreetONLINE Redaktion |
Shortseller bluten: Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein! 14.05.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,5560 | +28,17 | |
0,7062 | +23,76 | |
0,8599 | +15,81 | |
1,2840 | +14,03 | |
3,2800 | +13,10 |
Wertpapier | Kurs | Perf. % |
---|---|---|
2,7600 | -26,20 | |
1,1600 | -35,20 | |
0,5541 | -40,93 | |
0,9500 | -43,11 | |
4,7000 | -44,71 |
Beitrag zu dieser Diskussion schreiben
Antwort auf Beitrag Nr.: 37.760.537 von basset69 am 12.08.09 10:00:23also nochmals, ihr seid auch der Meinung, dass nur Institutionelle und Banken am Vorbörslichen Handel teilnehmen können und keine "Kleinanleger". So wurde es mir auch von einer Grossbank mitgeteilt.
Wenn dem so ist, sind also Grossinvestoren in letzter Zeit vorbörslich geneigt höhere Kurse zu zahlen, was ich mal als gut bezeichnen würde.
Meinungen/Anregungen?
Wenn dem so ist, sind also Grossinvestoren in letzter Zeit vorbörslich geneigt höhere Kurse zu zahlen, was ich mal als gut bezeichnen würde.
Meinungen/Anregungen?
Antwort auf Beitrag Nr.: 37.760.447 von basset69 am 12.08.09 09:51:26Novavax (NVAX) Bullish Technical Alert - Trend Up
Aug 11, 2009 (SmarTrend(R) Spotlight via COMTEX)
----Novavax (NASDAQ:NVAX) is trading 3.2% higher (up $0.16 to $5.09) today on volume of 567,484 shares. The stock is trading near its 52-week high of $5.59. We are watching for a close above that level.
Novavax is currently above its 50-day moving average of $3.10 and above its 200-day moving average of $1.98.
SmarTrend is bullish on shares of NVAX and our subscribers received an Uptrend alert on April 24, 2009 at $1.15, which has returned 342.6% to date.
http://www.foxbusiness.com/story/markets...
Aug 11, 2009 (SmarTrend(R) Spotlight via COMTEX)
----Novavax (NASDAQ:NVAX) is trading 3.2% higher (up $0.16 to $5.09) today on volume of 567,484 shares. The stock is trading near its 52-week high of $5.59. We are watching for a close above that level.
Novavax is currently above its 50-day moving average of $3.10 and above its 200-day moving average of $1.98.
SmarTrend is bullish on shares of NVAX and our subscribers received an Uptrend alert on April 24, 2009 at $1.15, which has returned 342.6% to date.
http://www.foxbusiness.com/story/markets...
Antwort auf Beitrag Nr.: 37.760.438 von basset69 am 12.08.09 09:50:19http://finance.yahoo.com/q/hp?s=NVAX&a=11&b=13&c=1995&d=7&e=…
und noch ein Link zur Beruhigung
und noch ein Link zur Beruhigung
Antwort auf Beitrag Nr.: 37.759.159 von KaOzz am 11.08.09 23:59:18"for major institutional players and high-net worth individuals"
dann ist es ja gut, wenn nvax vorbörslich steigt ...
dann ist es ja gut, wenn nvax vorbörslich steigt ...
Antwort auf Beitrag Nr.: 37.759.147 von KaOzz am 11.08.09 23:56:43Understanding Pre-Market and After-Hours Stock Trading
http://www.nasdaq.com/newscontent/20090216/understanding-pre…
http://www.nasdaq.com/newscontent/20090216/understanding-pre…
Antwort auf Beitrag Nr.: 37.755.776 von 360 am 11.08.09 17:07:27Hei!
http://en.wikipedia.org/wiki/Pre-market_trading" target="_blank" rel="nofollow ugc noopener">
http://en.wikipedia.org/wiki/Pre-market_trading
Und der hier is auch sehr aufschlussreich:
http://en.wikipedia.org/wiki/After-hours_trading
Alles in allem hängts wohl davon ab, ob Dein Broker das anbietet.
http://en.wikipedia.org/wiki/Pre-market_trading" target="_blank" rel="nofollow ugc noopener">
http://en.wikipedia.org/wiki/Pre-market_trading
Und der hier is auch sehr aufschlussreich:
http://en.wikipedia.org/wiki/After-hours_trading
Alles in allem hängts wohl davon ab, ob Dein Broker das anbietet.
Antwort auf Beitrag Nr.: 37.754.288 von basset69 am 11.08.09 14:56:57einmal mehr komischer Kursverlauf - Vorbörslich meistens Top dann im Handel Flop Nochmals wer kann Vorbörslich handeltn, doch nur Banken und Grosskunden oder??
Antwort auf Beitrag Nr.: 37.750.790 von basset69 am 11.08.09 08:41:33Na also, geht doch ...
Pre-Market High: $ 5.37
Pre-Market Low: $ 4.97
aktuell 5.22
Volume: 106,493 Pre-Market
Pre-Market High: $ 5.37
Pre-Market Low: $ 4.97
aktuell 5.22
Volume: 106,493 Pre-Market
Antwort auf Beitrag Nr.: 37.747.346 von basset69 am 10.08.09 18:18:51http://timesofindia.indiatimes.com/news/... 11-Aug-09 01:21 am
AHMEDABAD: Cadila Pharmaceutical Limited, an Ahmedabad-based unlisted pharma major, hopes to be the first to launch the vaccine for swine flu virus H1N1 by November this year!
CPL had set up a joint venture (JV) on July 9 with the US-based vaccine maker Novavax for manufacturing of vaccines, including one for swine flu. The JV company called CPL Biologicals Pvt Ltd is filling application with Drug Controller General of India (DCGI) this week for phase one clinical trial for swine flu vaccine.
Company officials were confident Cadila will be the first Indian pharma company to produce the swine flu vaccine. “Novavax has already received permission for pre-clinical trials from US Federal Drug Administration,” IA Modi, chairman and managing director, CPL, told TOI.
Modi said the vaccine is expected to be available in November 2009 if permission for clinical trial comes from the government immediately. The government has already decided to clear swine flu related applications on fast track basis.
Modi said to protect from swine flu pandemic, two dosages of the vaccine are required over two weeks. The company initially intends to produce 2 million vaccine on a monthly basis and scale up production to cater to global demand, Modi said. “Sky is the limit as far as production is concerned,” he said.
The JV has already started building a facility costing Rs 100 crore in the CPL campus at Bhat to produce the vaccines. The new facilities will be operational after one-and-a-half years but the company will be able to launch the vaccine in November, using existing manufacturing capacity of CPL.
CPL has 80% equity and Novavax 20% in the JV. It may be pointed out that Cadila Pharma also holds 5.75% equity stake in Novavax Inc USA and has a position on the board of directors of Novavax.
AHMEDABAD: Cadila Pharmaceutical Limited, an Ahmedabad-based unlisted pharma major, hopes to be the first to launch the vaccine for swine flu virus H1N1 by November this year!
CPL had set up a joint venture (JV) on July 9 with the US-based vaccine maker Novavax for manufacturing of vaccines, including one for swine flu. The JV company called CPL Biologicals Pvt Ltd is filling application with Drug Controller General of India (DCGI) this week for phase one clinical trial for swine flu vaccine.
Company officials were confident Cadila will be the first Indian pharma company to produce the swine flu vaccine. “Novavax has already received permission for pre-clinical trials from US Federal Drug Administration,” IA Modi, chairman and managing director, CPL, told TOI.
Modi said the vaccine is expected to be available in November 2009 if permission for clinical trial comes from the government immediately. The government has already decided to clear swine flu related applications on fast track basis.
Modi said to protect from swine flu pandemic, two dosages of the vaccine are required over two weeks. The company initially intends to produce 2 million vaccine on a monthly basis and scale up production to cater to global demand, Modi said. “Sky is the limit as far as production is concerned,” he said.
The JV has already started building a facility costing Rs 100 crore in the CPL campus at Bhat to produce the vaccines. The new facilities will be operational after one-and-a-half years but the company will be able to launch the vaccine in November, using existing manufacturing capacity of CPL.
CPL has 80% equity and Novavax 20% in the JV. It may be pointed out that Cadila Pharma also holds 5.75% equity stake in Novavax Inc USA and has a position on the board of directors of Novavax.
Antwort auf Beitrag Nr.: 37.746.984 von basset69 am 10.08.09 17:43:17klar, dass sie bei diesen news steigt ..
zur erinnerung:
Novavax of Rockville and Cadila Pharmaceuticals of Ahmedabad, India, have launched their previously announced joint venture in India, CPL Biologicals Pvt. Ltd., to develop and manufacture vaccines, biological therapeutics and diagnostics in India using technology from Novavax and Cadila Pharmaceuticals.
CPL Biologicals also plans to establish manufacturing facilities in India and develop, produce and market products such as seasonal influenza vaccine and other vaccines against dengue fever and chikungunya fever based on Novavax's virus-like-particle vaccine technology.
zur erinnerung:
Novavax of Rockville and Cadila Pharmaceuticals of Ahmedabad, India, have launched their previously announced joint venture in India, CPL Biologicals Pvt. Ltd., to develop and manufacture vaccines, biological therapeutics and diagnostics in India using technology from Novavax and Cadila Pharmaceuticals.
CPL Biologicals also plans to establish manufacturing facilities in India and develop, produce and market products such as seasonal influenza vaccine and other vaccines against dengue fever and chikungunya fever based on Novavax's virus-like-particle vaccine technology.
23.05.24 · wallstreetONLINE Redaktion · Pfizer |
Shortseller bluten: Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein! 14.05.24 · wallstreetONLINE Redaktion · Sanofi |
13.05.24 · Der Aktionär TV · Apple |
10.05.24 · dpa-AFX · McDonald's |
10.05.24 · dpa-AFX · 3M |
10.05.24 · dpa-AFX · Enel |
10.05.24 · dpa-AFX · 3M |
10.05.24 · dpa-AFX · Sanofi |